LEXINGTON, Mass.--(BUSINESS WIRE)--
Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has
appointed James V. Cassella, Ph.D. as Chief Development Officer. In this
newly created role, Dr. Cassella will lead Concert's product development
strategy and operations and will have responsibility for all
preclinical, clinical and manufacturing activities.
"Jim has extensive experience leading the development of both novel
compounds and reformulations of existing drugs for new indications,"
said Roger Tung, Ph.D., President and Chief Executive Officer of Concert
Pharmaceuticals. "His broad experience base and proven leadership skills
will be a great asset to Concert as we continue to advance and broaden
our clinical pipeline. We are excited to have Jim join Concert at this
important time in our further evolution as a product development
Dr. Cassella brings to Concert more than 25 years of experience in drug
development, including experience with product development, clinical
trial design and execution, regulatory affairs, and product registration
in the US and EU. Most recently, Dr. Cassella served as Executive Vice
President, Research and Development and Chief Scientific Officer of
Alexza Pharmaceuticals, Inc. Prior to Alexza Pharmaceuticals, Dr.
Cassella held various management positions at Neurogen Corporation,
including Senior Vice President, Clinical Research and Development.
Before joining the biotechnology industry, Dr. Cassella was Assistant
Professor of Neuroscience at Oberlin College. Dr. Cassella received a
Ph.D. in Physiological Psychology from Dartmouth College, completed a
postdoctoral fellowship in the Department of Psychiatry at the Yale
University School of Medicine and received a B.A. in psychology from the
University of New Haven.
Concert Pharmaceuticals is a clinical stage biopharmaceutical company
focused on applying its DCE Platform® (deuterated chemical entity
platform) to create novel small molecule drugs. This approach starts
with approved drugs, advanced clinical candidates or previously studied
compounds that have the potential to be improved with deuterium
substitution to enhance clinical safety, tolerability or efficacy. The
company is developing a broad pipeline targeting CNS disorders, renal
disease, inflammation and cancer. For more information, please visit www.concertpharma.com.
Concert Pharmaceuticals Inc., the CoNCERT Pharmaceuticals Inc. logo and
DCE Platform are registered trademarks of Concert Pharmaceuticals, Inc.
Concert Pharmaceuticals, Inc.
Justine Koenigsberg (Investors),
Kathryn Morris (Media), 845-635-9828
Source: Concert Pharmaceuticals, Inc.
News Provided by Acquire Media